Beyond a biomarker: Integrating personalized ctDNA to inform gyn oncology care
Activity Overview
The GOG Foundation, Inc. and GOG Partners welcome gynecologic oncologists, oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with gynecologic malignancies to attend the Beyond a biomarker: Integrating personalized ctDNA to inform gyn oncology care Industry Supported Symposium being held in-person at the IGCS 2026 Annual Global Meeting in Montreal, Canada on Friday, October 2, 2026, from 7:15 – 8:00 AM EDT.
Gynecologic oncologists increasingly face decisions about adjuvant therapy, maintenance treatment, surveillance intensity, and recurrence management that are not fully addressed by imaging and serum biomarkers alone. ctDNA offers an opportunity method to detect molecular disease burden, assess treatment effectiveness, identify residual disease, and detect recurrence earlier than conventional approaches. However, clinicians need practical guidance regarding interpretation, evidence strength, limitations, and integration into multidisciplinary care pathways.
This educational activity is supported by an independent medical education grant from Natera
Target Audience
The target audience for this activity is community and academic gynecologic oncologists, oncologists, advanced practitioners (NP/PA/PharmD), and other providers who treat patients with gynecologic malignancies.
Learning Objectives
By the end of this activity, participants will be able to:
- Explain how ctDNA functions as a real-time measure of tumor burden across the gynecologic cancer continuum.
- Compare the strengths and limitations of ctDNA, imaging, CA-125, HE4, pathology, and clinical assessment at key treatment decision points.
- Evaluate current evidence supporting ctDNA-guided risk stratification, treatment monitoring, MRD assessment, and recurrence detection in ovarian, endometrial, and cervical cancers.
- Apply ctDNA results within multidisciplinary treatment planning through case-based patient journeys.
- Recognize current limitations, ongoing clinical trials, and areas where evidence remains insufficient for routine adoption.
Faculty
Jubilee Brown, MD
Levine Cancer Institute, Atrium Health
Bradley Monk, MD
Florida Cancer Specialists & Research Institute
Agenda
Jubilee Brown, MD
Levine Cancer Institute, Atrium Health
Jubilee Brown, MD
Levine Cancer Institute, Atrium Health
Bradley Monk, MD
Florida Cancer Specialists & Research Institute
Jubilee Brown, MD
Levine Cancer Institute, Atrium Health
Bradley Monk, MD
Florida Cancer Specialists & Research Institute
All Faculty